VESANOID 10 MG — DIN 02145839
TRETINOIN : 10 MG · CHEPLAPHARM ARZNEIMITTEL GMBH · CAPSULE · wholesale supply in Canada
Health Canada status: MARKETED
What is VESANOID?
VESANOID 10 MG contains TRETINOIN : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02145839, held by CHEPLAPHARM ARZNEIMITTEL GMBH, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 21-Oct-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is VESANOID used for?
Induction of remission in acute promyelocytic leukemia (APL; FAB classification AML-M3). Includes previously untreated, relapsed, or refractory patients.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Tretinoin cost around the world?
Tretinoin is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory); Iceland publishes a max wholesale. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 7 | 56 | USD███.██ |
| Saudi Arabia | public | 14 | 16 | SAR███.██ |
| South Africa | single exit price | 6 | 8 | ZAR███.██ |
| United Arab Emirates | public | 7 | 7 | AED███.██ |
| Bahrain | retail (max) | 3 | 5 | BHD███.██ |
| Lebanon | public price (USD, Decision 119/1) | 1 | 3 | USD███.██ |
| Czechia | max producer price (ex-factory) | 2 | 2 | CZK███.██ |
| Iceland | max wholesale | 1 | 1 | ISK███.██ |
| Luxembourg | reimbursement | 1 | 1 | EUR███.██ |
99 pack listings across 42 brand entries and 8 price bases, refreshed 05 Sep 2026. Ranges span every Tretinoin pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Tretinoin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
2 holders have a Canadian DIN containing Tretinoin, across 2 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| CHEPLAPHARM ARZNEIMITTEL GMBH | 1 | 1 | VESANOID | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 1 | 1 | JAMP TRETINOIN | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 10 MG |
|---|---|
| Dosage form | CAPSULE |
| Route | ORAL |
| Pack configuration (monograph) | Bottles of 100 capsules. |
| Storage | Not explicitly detailed in provided text (section 11 mentioned in TOC but text cuts off). Standard practice is 15-30°C. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Tretinoin |
|---|---|
| ATC code | L01XF01 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02145839 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2145839 |
| Brand name | VESANOID |
| Generic / active ingredient | TRETINOIN : 10 MG |
| Market authorization holder | CHEPLAPHARM ARZNEIMITTEL GMBH |
| Health Canada schedule | Prescription |
| ATC code | L01XF01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01XF |
| Current status | MARKETED |
| Status date | 21-Oct-2013 |
| Original market date | 1995-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
45 mg/m2 daily divided into two equal doses. Continue for 30-90 days until remission. Swallow whole with water, preferably with a meal.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to tretinoin or ingredients; pregnancy and nursing mothers; use with vitamin A, tetracyclines, or other retinoids.
Warnings and precautions
Serious risk of teratogenicity; Differentiation Syndrome (may be fatal); Hyperleukocytosis; Retinoic Acid Syndrome; Intracranial hypertension; Thrombosis risk.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 2 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP TRETINOIN | 10 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | 02520036 |
2 · Same class — other molecules in ATC L01XF
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Tretinoin | JAMP TRETINOIN · VESANOID | 2 | 2 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01X
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01XX | Aflibercept · Altretamine · Amsacrine · Anagrelide · Arsenic Trioxide · +13 more | 48 | 23 |
| L01XG | Bortezomib · Carfilzomib · Ixazomib | 30 | 18 |
| L01XA | Carboplatin · Cisplatin · Oxaliplatin | 45 | 12 |
| L01XK | Niraparib · Niraparib And Abiraterone · Olaparib · Talazoparib | 12 | 7 |
| L01XL | Axicabtagene Ciloleucel · Brexucabtagene Autoleucel · Ciltacabtagene Autoleucel · Idecabtagene Vicleucel · Lifileucel · +2 more | 8 | 5 |
| L01XJ | Glasdegib · Sonidegib · Vismodegib | 4 | 4 |
| L01XD | Aminolevulinic Acid · Methyl Aminolevulinate · Porfimer Sodium | 5 | 3 |
| L01XH | Romidepsin · Vorinostat | 2 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is VESANOID called?
The same molecule, Tretinoin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| ACRETIN | Latin | Bahrain, Saudi Arabia |
| TRETINOIN | Latin | Lebanon |
| Airol | Latin | South Africa |
| AVOTIN- A | Latin | Saudi Arabia |
| OPTIMAL | Latin | Bahrain |
| Retin A | Latin | South Africa |
| A - Ret | Latin | United Arab Emirates |
| ACNATAC | Latin | Czechia |
| ACNELIN | Latin | Saudi Arabia |
| AKNEMYCIN PLUS | Latin | Czechia |
| AVOTIN-A | Latin | Bahrain |
| Ilotycin A Gel | Latin | South Africa |
| Ilotycin-A Cream | Latin | South Africa |
| Retacnyl | Latin | South Africa |
| SMOODERM CREAM | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.